Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement with the CHARITÉ artificial disc versus lumbar fusion: Five-year follow-up

医学 试验装置豁免 退行性椎间盘病 Oswestry残疾指数 可视模拟标度 随机对照试验 外科 腰椎 背景(考古学) 腰椎 前瞻性队列研究 临床试验 腰痛 内科学 替代医学 病理 古生物学 生物
作者
Richard D. Guyer,Paul C. McAfee,Robert Banco,Fabien D. Bitan,Andrew Cappuccino,Fred H. Geisler,Stephen H. Hochschuler,Richard T. Holt,Louis G. Jenis,Mohamed E. Majd,John M. Regan,Scott Tromanhauser,Douglas Wong,Scott L. Blumenthal
出处
期刊:The Spine Journal [Elsevier]
卷期号:9 (5): 374-386 被引量:273
标识
DOI:10.1016/j.spinee.2008.08.007
摘要

Background context The CHARITÉ artificial disc, a lumbar spinal arthroplasty device, was approved by the United States Food and Drug Administration in 2004 based on two-year safety and effectiveness data from a multicenter, prospective, randomized investigational device exemption (IDE) study. No long-term, randomized, prospective study on the CHARITÉ disc or any other artificial disc has been published to date. Purpose The purpose of this study was to compare the safety and effectiveness at the five-year follow-up time point of lumbar total disc replacement using the CHARITÉ artificial disc (DePuy Spine, Raynham, MA) with that of anterior lumbar interbody fusion (ALIF) with BAK cages and iliac crest autograft, for the treatment of single-level degenerative disc disease from L4 to S1, unresponsive to nonoperative treatment. Study design/setting Randomized controlled trial—five-year follow-up. Patient sample Ninety CHARITÉ patients and 43 BAK patients. Outcome measures Self-reported measures: visual analog scale (VAS); validated Oswestry disability index (ODI version 1.0); Short-Form 36 Questionnaire, and patient satisfaction. Physiologic measures: radiographic range of motion, disc height, and segmental translation. Functional measures: work status. Methods Of the 375 subjects enrolled in the CHARITÉ IDE trial, 277 were eligible for the five-year study and 160 patients thereof completed the five-year follow-up. The completers included 133 randomized patients. Overall success was defined as improvement≥15 pts in ODI vs. baseline, no device failure, absence of major complications, and maintenance or improvement of neurological status. Additional clinical outcomes included an ODI questionnaire as well as VAS, SF-36, and patient satisfaction surveys. Work status was tracked for all patients. Safety assessments included occurrence and severity of adverse events and device failures. Radiographic analyses such as index- and adjacent-level range of motion, segmental translation, disc height, and longitudinal ossification were also carried out. Results Overall success was 57.8% in the CHARITÉ group vs. 51.2% in the BAK group (Blackwelder's test: p=0.0359, Δ=0.10). In addition, mean changes from baseline for ODI (CHARITÉ: −24.0 pts vs. BAK: −27.5 pts), VAS pain scores (CHARITÉ: −38.7 vs. BAK: −40.0), and SF-36 questionnaires (SF-36 Physical Component Scores [PCS]: CHARITÉ: 12.6 pts vs. BAK: 12.3 pts) were similar across groups. In patient satisfaction surveys, 78% of CHARITÉ patients were satisfied vs. 72% of BAK patients. A total of 65.6% patients in the CHARITÉ group vs. 46.5% patients in the BAK group were employed full-time. This difference was statistically significant (p=0.0403). Long-term disability was recorded for 8.0% of CHARITÉ patients and 20.9% of BAK patients, a difference that was also statistically significant (p=0.0441). Additional index-level surgery was performed in 7.7% of CHARITÉ patients and 16.3% of BAK patients. Radiographic findings included operative and adjacent-level range of motion (ROM), intervertebral disc height and segmental translation. At the five-year follow-up, the mean ROM at the index level was 6.0° for CHARITÉ patients and 1.0° for BAK patients. Changes in disc height were also similar for both CHARITÉ and BAK patients (0.7 mm for both groups, p=0.9827). Segmental translation was 0.4 and 0.8 mm in patients implanted with CHARITÉ at L4–L5 vs. L5–S1, respectively, and 0.1 mm in BAK patients. Conclusions The results of this five-year, prospective, randomized multicenter study are consistent with the two-year reports of noninferiority of CHARITÉ artificial disc vs. ALIF with BAK and iliac crest autograft. No statistical differences were found in clinical outcomes between groups. In addition, CHARITÉ patients reached a statistically greater rate of part- and full-time employment and a statistically lower rate of long-term disability, compared with BAK patients. Radiographically, the ROMs at index- and adjacent levels were not statistically different from those observed at two-years postsurgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优美匕完成签到,获得积分10
1秒前
dr1nk完成签到,获得积分10
1秒前
薛定谔的猫完成签到,获得积分10
1秒前
MayorWang完成签到,获得积分10
1秒前
爆米花应助Ykc采纳,获得10
2秒前
apple发布了新的文献求助10
2秒前
Lh6610完成签到,获得积分0
2秒前
阿飞完成签到,获得积分10
2秒前
小神仙完成签到,获得积分20
2秒前
you完成签到,获得积分20
2秒前
乐怡日尧发布了新的文献求助10
3秒前
雅雅发布了新的文献求助10
4秒前
Cat应助科研通管家采纳,获得10
4秒前
ding应助科研通管家采纳,获得20
4秒前
思源应助科研通管家采纳,获得10
4秒前
4秒前
斯文败类应助科研通管家采纳,获得10
4秒前
5秒前
bkagyin应助科研通管家采纳,获得10
5秒前
小蘑菇应助科研通管家采纳,获得10
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
Zion完成签到,获得积分10
5秒前
orixero应助科研通管家采纳,获得10
5秒前
pcr163应助科研通管家采纳,获得50
5秒前
科目三应助科研通管家采纳,获得10
5秒前
ding应助科研通管家采纳,获得10
5秒前
斯文败类应助wuxunxun2015采纳,获得10
5秒前
阿飘应助科研通管家采纳,获得10
5秒前
务实的伯云完成签到,获得积分20
5秒前
5秒前
星辰大海应助快醒醒吖佳采纳,获得10
7秒前
nn完成签到,获得积分10
7秒前
lilyz615完成签到,获得积分10
7秒前
虚心的仙人掌完成签到,获得积分10
7秒前
余南完成签到,获得积分10
8秒前
鲤鱼松鼠完成签到,获得积分10
8秒前
9秒前
凯里欧文完成签到,获得积分10
9秒前
hezi完成签到,获得积分10
9秒前
9秒前
高分求助中
Handbook of Fuel Cells, 6 Volume Set 1666
Floxuridine; Third Edition 1000
Tracking and Data Fusion: A Handbook of Algorithms 1000
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 800
消化器内視鏡関連の偶発症に関する第7回全国調査報告2019〜2021年までの3年間 500
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 500
Framing China: Media Images and Political Debates in Britain, the USA and Switzerland, 1900-1950 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 冶金 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2860902
求助须知:如何正确求助?哪些是违规求助? 2466168
关于积分的说明 6685429
捐赠科研通 2157336
什么是DOI,文献DOI怎么找? 1146061
版权声明 585087
科研通“疑难数据库(出版商)”最低求助积分说明 563140